Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sanofi SA, in collaboration with Kymera Therapeutics, is conducting a Phase 2 clinical study titled A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis. The study aims to assess the efficacy and safety of SAR444656, a potential systemic treatment for adults with moderate to severe atopic dermatitis who are inadequately controlled with topical therapies.
The intervention being tested is SAR444656 (KT-474), an oral tablet administered in three different doses, compared to a placebo. The goal is to determine its effectiveness in treating atopic dermatitis.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide a new therapeutic option for atopic dermatitis.
The study began on November 9, 2023, with an estimated completion date in 2025. The last update was submitted on July 8, 2025, indicating ongoing progress in the trial.
Sanofi’s advancement in this study could influence its stock performance positively, as successful results may lead to a new marketable treatment for atopic dermatitis, a condition with significant unmet needs. Investors should monitor this development, considering the competitive landscape of dermatological treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.